SLC5A2 and autosomal dominant polycystic kidney disease: To date, there is insufficient evidence regarding the use of these drugs in patients with ADPKD, as those were excluded from several clinical trials conducted to explore the kidney protection provided by SGLT2 inhibitors [8,10].